790 related articles for article (PubMed ID: 21263095)
1. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
2. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Gollins SW; Myint S; Susnerwala S; Haylock B; Wise M; Topham C; Samuel L; Swindell R; Morris J; Mason L; Levine E
Br J Cancer; 2009 Sep; 101(6):924-34. PubMed ID: 19690550
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
[TBL] [Abstract][Full Text] [Related]
7. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
11. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
12. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
13. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
16. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Lee SU; Kim DY; Kim SY; Baek JY; Chang HJ; Kim MJ; Kim TH; Park JW; Oh JH
Radiat Oncol; 2013 Nov; 8():258. PubMed ID: 24188746
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]